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ABSTRACT
Cancer-associated fibroblasts (CAFs) are an emerging target for cancer therapy 
as they promote tumour growth and metastatic potential. However, CAF targeting 
is complicated by the lack of knowledge-based strategies aiming to selectively 
eliminate these cells. There is a growing body of evidence suggesting that a pro-
inflammatory microenvironment (e.g. ROS and cytokines) promotes CAF formation 
during tumorigenesis, although the exact mechanisms involved remain unclear. In 
this study, we reveal that a prolonged pro-inflammatory stimulation causes a de facto 
deficiency in base excision repair, generating unrepaired DNA strand breaks and thereby 
triggering an ATF4-dependent reprogramming of normal fibroblasts into CAF-like cells. 
Based on the phenotype of in vitro-generated CAFs, we demonstrate that midostaurin, 
a clinically relevant compound, selectively eliminates CAF-like cells deficient in base 
excision repair and prevents their stimulatory role in cancer cell growth and migration.
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 INTRODUCTION
Cancer cells heavily depend on a microenvironment 
that sustains their metabolism and proliferation, promotes 
their survival and ensures their ability to migrate and 
invade the surrounding tissue [1]. One main component 
of the tumour microenvironment is the stromal fibroblast, 
often referred to as cancer-associated fibroblast (CAF) [1]. 
CAFs are generally described as “activated fibroblasts”, 
hardly distinguishable from myofibroblasts [2] that have 
undergone trans-differentiation and show increased 
expression of specific markers (e.g. α-smooth muscle 
actin (α-SMA), fibroblast activation protein (FAP), 
secreted protein acidic and rich in cysteine (SPARC) or 
platelet-derived growth factor receptor β (PDGFRβ)) [3], 
accompanied by a pro-inflammatory secretory signature [4] 
and an enhanced extra-cellular matrix (ECM) remodelling 
capacity [2]. 
Understanding the molecular events driving 
fibroblast trans-differentiation is of great importance for 
developing new strategies for cancer treatment and for 
identifying novel anticancer drugs. It is well established 
that CAF genesis is mediated by inflammation through 
cytokines (e.g. transforming growth factor β (TGFβ)) 
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and/or reactive oxygen species (ROS) [5, 6]. However, 
it remains unclear how TGFβ or ROS may condition 
fibroblasts and drive their change into CAFs on a 
molecular basis. Importantly, ROS can target DNA and 
induce a wide range of oxidative DNA lesions [7], which 
are usually eliminated by the base excision repair (BER) 
pathway [8]. BER is a robust DNA repair pathway that 
processes multiple endogenous DNA lesions including base 
damage and DNA single strand breaks (SSBs), as well as 
acute DNA damage caused by many mutagens. However, 
despite the high capacity of BER, persistent exposure to 
DNA damaging agents might overload BER capacity and 
result in accumulation of unrepaired DNA damage [9]. 
Indeed, we have recently demonstrated that accumulation 
of unrepaired SSBs in normal human fibroblasts leads to 
a cellular response whose proteomic profile is reminiscent 
of that observed in CAFs and cancer cells [10]. Therefore, 
we hypothesised that persistent DNA damage induced 
by ROS within the tumour microenvironment may lead 
to accumulation of unrepaired DNA strand breaks and 
reprogramming of normal fibroblasts into CAFs.
In this study, we demonstrate that a prolonged pro-
inflammatory response can cause a deficiency in BER. 
This leads to an accumulation of unrepaired SSBs and 
induces trans-differentiation of normal human fibroblasts 
into CAF-like cells. Based on these findings we identified 
midostaurin, a clinically relevant compound, as a drug that 
selectively eliminates BER deficiency generated CAF-
like cells and prevents their stimulatory role in cancer cell 
growth and migration. 
RESULTS
Persistent exposure of fibroblasts to ROS or 
TGFβ promotes a decrease in BER capacity and 
accumulation of unrepaired DNA strand breaks, 
leading to trans-differentiation into CAF-like cells
Can unrepaired DNA strand breaks act as a 
trigger for trans-differentiation of normal fibroblasts? 
Tumours generally develop within a pro-inflammatory 
microenvironment, where a sustained release of pro-
inflammatory and pro-fibrotic cytokines (e.g. TGFβ) by a 
variety of cell types accompanied by an increase in ROS 
production promote the generation of CAFs5. Accordingly, 
normal human TIG-1 fibroblasts treated for 72 hours with 
either H2O2 or TGFβ showed increased expression of 
markers such as α-SMA and PALLD, indicating that these 
experimental conditions induce an activated fibroblast 
signature (Figure 1A and 1B). Likewise, TGFβ treatment 
triggered an increase in the expression of the activated 
fibroblast markers, SPARC and FAP (Supplementary 
Figure 1A). Surprisingly, after treatment of the cells with 
H2O2 or TGFβ we also observed a concomitant loss of 
XRCC1–a BER protein essential for repair of SSBs arising 
due to endogenous mutagens [11] (Figure 1A and 1B). 
This decrease in XRCC1 was accompanied by an impaired 
BER capacity, as assessed by in vitro DNA repair assays, 
similar to what is observed after XRCC1 depletion by 
siRNA (Figure 1C). ROS are known to induce a variety 
of DNA lesions, including SSBs [7]; and over a prolonged 
exposure, could create a situation of persistent cellular 
stress and eventually exhaust BER capacity. With this in 
mind, we tested whether prolonged exposure of fibroblasts 
to either ROS or TGFβ could lead to an accumulation of 
unrepaired DNA damage. Indeed, persistent exposure 
of normal fibroblasts to H2O2 or TGFβ for 72 h led 
to accumulation of unrepaired DNA strand breaks, as 
measured by alkaline comet assays (Figure 1D) and by 
formation of 53BP1 foci (Supplementary Figure 1B). In 
addition, continuous exposure to TGFβ also resulted in an 
increase in intracellular ROS (Figure 1E), approximately 
equivalent to 18 mM H2O2 as calculated using a standard 
curve (Supplementary Figure 1C), thus explaining why 
fibroblasts treated with this pro-fibrotic cytokine showed 
accumulation of DNA damage. These results indicate that 
prolonged exposure to an oxidative microenvironment 
causes an exhaustion of BER that leads to accumulation of 
unrepaired DNA strand breaks in fibroblasts, concomitant 
with the induction of a CAF-like signature. 
A large number of macromolecules can be modified 
by ROS. Our results suggested that, in the context of 
fibroblast trans-differentiation, ROS or DNA strand breaks 
could be a driving force for the emergence of CAFs. We 
thus wanted to address whether the exhaustion of BER 
could be a mechanism to amplify the stress response and 
trigger the trans-differentiation.
To answer these questions, we made use of a cellular 
model of BER deficiency generated by knockdown 
of expression of the XRCC1 protein that has been 
thoroughly characterised in our laboratory [10]. In this 
model, XRCC1 KD causes accumulation of SSBs in the 
absence of detectable DNA double strand breaks (DSBs) 
[12]. Interestingly, depletion of XRCC1 in normal 
human fibroblasts (hereafter XRCC1 KD cells) led to 
an accumulation of DNA damage comparable to a level 
observed when fibroblasts are treated with H2O2 or TGFβ 
(Figure 1D). Furthermore, in contrast to cells treated with 
H2O2 or TGFβ, XRCC1 KD fibroblasts did not show any 
increase in intracellular ROS (Figure 1E). This prompted 
us to exploit XRCC1 KD cells to investigate whether 
unrepaired SSBs alone, independently of DSBs or oxidative 
stress, can trigger trans-differentiation into CAF-like cells. 
XRCC1 depletion leads to ATF4-dependent 
reprogramming of normal fibroblasts and 
the emergence of a gene expression signature 
characteristic of CAFs
We have previously performed proteome-wide 
analysis on normal human fibroblasts depleted of XRCC1 
[10]. This analysis suggested that the proteomic profile of 
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Figure 1: Persistent exposure of fibroblasts to ROS or TGFβ leads to a decrease of BER capacity. (A–B) Effect of 
H2O2 or TGFβ on XRCC1, α-SMA and PALLD levels. (A) TIG-1 fibroblasts were treated for 72 h with H2O2 or TGFβ at the indicated 
concentrations, H2O2 was administered every 24 h. Cells were analysed by immunofluorescence using antibodies staining for α-SMA and 
XRCC1. Nuclei were stained with Hoechst. Scale bars: 50 μm. In (B) TIG-1 fibroblasts were treated for 72 h with either 125 μM H2O2 
or 10 ng/ml TGFβ. Protein expression was analysed by Western blot. (C) Effect of H2O2 and TGFβ on BER capacity. Cells were treated 
as described in (B) and BER capacity was assessed by the in vitro repair assay using nuclear cell extracts generated from the indicated 
samples. The plot shows the percentage of substrate to product conversion over time using in vitro ligation assays as described in “Material 
and methods”. (D) Effect of H2O2 and TGFβ on DNA damage accumulation. TIG-1 fibroblasts were treated as in (B) or depleted for 
XRCC1 by means of siRNA. DNA damage accumulation was assessed 72h later using the alkaline comet assay.  (E) Effect of TGFβ (10 
ng/ml), H2O2 (20 μM), or XRCC1 depletion on the levels of intracellular ROS. TIG-1 fibroblasts were treated as indicated and analysed 
by FACS for intracellular ROS content. Data are reported as mean ± SD of three independent experiments *p < 0.05; **p < 0.01. See also 
Supplementary Figure 1.
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XRCC1 KD cells was reminiscent of that usually observed 
in CAFs and tumour cells [10], indicating that fibroblasts 
experience major phenotypical rearrangements in response 
to persistent DNA damage.
To increase the resolution of our previous analysis 
we exploited the stable isotope labelling by amino acids in 
cell culture (SILAC) technology and specifically analysed 
the chromatin-bound proteome using the “chromatin 
enrichment for proteomics” (ChEP) methodology [13] 
(Figure 2A). Functional clustering of the merged data 
provided a landscape of the proteomic changes occurring 
in normal fibroblasts upon SSB accumulation induced 
by BER depletion. Strikingly, we observed major 
upregulation of proteins involved in cellular metabolism, 
signalling and ECM remodelling (Supplementary Table 1). 
These changes strongly resembled those typically found 
in CAFs [1, 5], with upregulation of palladin (PALLD), 
SPARC, caldesmon (CALD1), PDGF receptors (both 
α and β) and matrix metalloproteinase-2 (MMP2) 
(Supplementary Table 2).
To determine whether the observed proteomic 
profile was the consequence of a broad transcriptional 
reprogramming rather than differential protein stability, 
we analysed mRNA levels of a subset of hits identified in 
the SILAC analysis. For the majority of the selected genes 
deregulation was validated at the mRNA level, confirming 
that accumulation of unrepaired strand breaks, caused 
by XRCC1 depletion, induced a vast transcriptional 
reprogramming in fibroblasts (Figure 2B). In addition 
to the genes found in the SILAC analysis, we detected 
increased expression of FAP and α-SMA, as well as 
decreased levels of calveolin-1 (CAV1) (Supplementary 
Figure 2A and Supplementary Table 2), well-known CAF 
markers [5, 14]. Importantly, a similar gene expression 
profile was triggered by depletion of XRCC1 using 
different siRNA sequences (Supplementary Figure 2B) 
and in other fibroblast cell lines of foetal (Supplementary 
Figure 2C) and adult (Supplementary Figure 2D) origin, 
thus excluding both cell-line specific mechanisms and off-
target effects of the XRCC1 siRNA.
We have previously demonstrated activation of the 
transcription factor ATF4 upon XRCC1 depletion [10]. Here, 
we confirmed increased ATF4 expression in XRCC1 KD 
cells (Supplementary  Figure 2E). Furthermore, we found 
that simultaneous depletion of XRCC1 and ATF4 completely 
prevented the transcriptional upregulation of CAF markers 
such as FAP and α-SMA and partially the upregulation of 
PALLD, which were induced in XRCC1 KD fibroblasts 
(Figure 2C). ATF4 depletion itself caused a decrease in 
PALLD and α-SMA expression (Figure 2C), suggesting that 
it also controls the basal expression of these genes.  
Altogether, these results suggest that accumulation 
of unrepaired DNA strand breaks in BER-deficient 
fibroblasts is sufficient to drive a transcriptional 
reprogramming resembling that usually observed in CAFs. 
This reprogramming is dependent on the activation of the 
stress-responsive transcription factor ATF4. 
XRCC1 KD fibroblasts display functional 
characteristics similar to CAFs
As XRCC1 KD cells showed transcriptional markers 
typical of CAFs, we sought to determine whether unrepaired 
SSBs could actually lead to a CAF-like phenotype. 
Phenotypical characterisation of XRCC1 KD fibroblasts 
by α-tubulin staining revealed a modified cytoskeleton with 
thick aligned fibres and an elongated cell shape, a distinctive 
characteristic of activated fibroblasts (Figures 2D and 
Supplementary Figure 2F) [15]. Accordingly, XRCC1 KD 
cells showed increased contractility, as measured by in vitro 
collagen contraction assays (Figure 2E), and this phenotype 
correlated with increases in PALLD and α-SMA protein 
levels (Figures 2F, 2G, Supplementary Figure 2G, and 
2H), both of which promote cytoskeleton contraction and 
migration in CAFs [3, 16]. In line with these observations, 
XRCC1 KD cells showed increased migration, displaying 
greater dispersion (Figure 2H) and augmented velocity 
(Figure 2I), as assessed by single-cell tracking. Interestingly, 
these phenotypical changes were not transitory, as upon 
XRCC1 depletion PALLD failed to return to basal levels 
and cytoskeleton contraction persisted, even when XRCC1 
expression was partially restored (Supplementary Figure 
3A, 3B), suggesting terminal differentiation. 
Intracellular Ca2+ is essential for contraction of 
activated fibroblasts [17] and for the maintenance of their 
phenotype [18]. Accordingly, we found that suppression 
of Ca2+ release from the endoplasmic reticulum through 
inhibition of phospholipase C (PLC) activity led to 
relaxation of the cytoskeleton and decreased α-SMA 
staining in XRCC1 KD cells (Figure 3A), as well as 
prevention of the migratory phenotype (Figure 3B and 
3C). These observations further support the activated 
fibroblast phenotype of XRCC1 KD cells.
Additionally, CAFs affect their microenvironment 
through secretion of molecules such as growth factors and 
cytokines [1, 5]. XRCC1 KD cells showed high expression 
of the growth factors PDGF-D and connective tissue 
growth factor (CTGF) as well as the cytokine interleukin-6 
(IL-6) and attenuated expression of the tumour suppressor 
pentraxin-related protein PTX3, an important modulator of 
inflammation and immune response [19] (Figure 4A), all 
of which are changes characteristic of activated fibroblasts. 
Changes in several ECM components known to promote 
growth of tumour cells [1, 15], such as the collagens 
COL1A1, COL1A2, and the MMP2 metalloprotease 
(Figure 4A) were also evident in XRCC1 KD cells, again 
reflecting an activated fibroblast phenotype. In conclusion, 
trans-differentiation induced by BER deficiency in 
fibroblasts results in a CAF-like phenotype characterised 
by cytoskeleton contraction, increased migratory ability, 
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Figure 2: XRCC1 depletion leads to reprogramming of normal fibroblasts into CAF-like cells. (A) Schematic representation 
of the SILAC-based proteomics analysis. (B) Validation of protein expression changes at the transcriptional level. TIG-1 fibroblasts were 
transfected with either a non-targeting control siRNA (siCtrl), or an XRCC1-targeting siRNA for 72 h and expression of the indicated genes 
was analysed by qPCR. The dashed line represents the normalised expression level in siCtrl-treated cells. (C) Rescue of the expression 
of PALLD, FAP and α-SMA upon simultaneous depletion of XRCC1 and ATF4. Samples were analysed by qPCR 72 h after siRNA 
transfection. (D) XRCC1 KD fibroblasts show increased cytoskeleton density and an elongated shape. Cells were stained for α-tubulin (left 
panel). Nuclei were stained with Hoechst. Scale bars: 50 μm. Cell elongation ratio (right panel) was assessed by IN Cell high-throughput 
imagery, as described in Materials and methods. Statistical significance was evaluated by a non-parametric Mann-Whitney U Test. (E) 
XRCC1 depletion leads to contraction of the cytoskeleton.TIG-1 fibroblasts were treated as in (B) and analysed for contractility. Relative 
contraction was assessed using a collagen gel-based assay, as described in Materials and methods.  (F–G) XRCC1 depletion leads to 
increased expression of PALLD and α-SMA. TIG-1 fibroblasts were treated as in (B) and analysed by immunofluorescence (F) or western 
blotting (G). Cells were stained for PALLD and α-SMA. Nuclei were stained with Hoechst. Scale bars: 50 μm. (H–I) Effect of XRCC1 
depletion on fibroblast migration. Cells were incubated with the indicated siRNA for 48 h before the wound was generated and monitored 
through live microscopy for 20 h. Individual cells were manually tracked and their dispersion (H) or velocity (I) was calculated. Results are 
presented as mean ± SD of at least three independent experiments *p < 0.05; **p < 0.01; ***p < 0.001. 
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and augmented expression of secreted molecules that can 
promote cell growth and migration.
XRCC1 KD fibroblasts promote growth and 
invasion of cancer cells
The phenotype observed upon XRCC1 depletion 
suggests that, similarly to CAFs, XRCC1 KD cells might 
have tumour promoting properties. Thus, we assessed the 
ability of XRCC1 KD fibroblasts to support growth and 
motility of cancer cells. Notably, conditioned medium from 
two different lung-derived fibroblast lines with XRCC1 
KD, significantly stimulated the growth of non-small 
cell lung carcinoma-derived H1299 cells (Figure 4B and 
Supplementary Figure 4A) and lung carcinoma-derived 
A549 (Supplementary Figure 4B) cell lines. Similar effects 
could be seen with the bladder carcinoma-derived T24 cell 
line (Figure 4C and  Supplementary Figure 4C), suggesting 
that the phenomenon is not tissue-specific. Additionally, 
exposure of H1299 cells to medium conditioned by 
XRCC1 KD fibroblasts significantly enhanced their 
migratory properties (Figure 4D). Co-culturing XRCC1 
KD fibroblasts and H1299 cells in Boyden chamber assays 
stimulated the invasive capacity of the cancer cells (Figure 
4E). Similarly, when co-cultured as spheroids, XRCC1 KD 
fibroblasts significantly increased the invasive capability of 
H1299 cells (Figure 4F). Finally, migration assays on 3D 
matrix showed that XRCC1 KD fibroblasts were capable 
of forming network structures within the Matrigel matrix, 
supporting invasion of GFP-expressing H1299 cells out of 
the spheroids (Figure 4G).
Together, these data led us to conclude that 
unrepaired SSBs accumulating in BER-depleted cells can 
trigger the conversion of fibroblasts towards a CAF-like 
phenotype that supports growth, migration, invasion and 
tumorigenic capabilities of cancer cells.
Figure 3: Calcium release is required for cytoskeleton contraction and migration of XRCC1 KD fibroblasts. (A) Effect 
of PLC inhibition on cytoskeleton contraction. TIG-1 fibroblasts were treated with the indicated siRNA for 72 h. The PLC inhibitor 
edelfosine (PLCi, 10 μm) was added during the final 48 h of the experiment. Cells were subsequently stained for α-tubulin and α-SMA. 
Nuclei were stained with Hoechst. Scale bars: 50 μm. (B–C) Effect of simultaneous XRCC1 depletion and PLC inhibition on fibroblast 
migration. TIG-1 fibroblasts were treated with the indicated siRNA and incubated with PLCi 24 h before the wound was generated and the 
acquisition was carried out under live cell microscopy for 20h. Individual cells were manually tracked to analyse their velocity (B) and 
dispersion (C).  ***p < 0.001.
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Figure 4: XRCC1 KD fibroblasts promote growth and migration of cancer cells.  (A) Effect of XRCC1 depletion on the 
expression of secreted proteins. TIG-1 fibroblasts were depleted of XRCC1 and expression of the indicated genes was analysed by qPCR. 
The dashed line represents the normalised expression level in cells treated with control siRNA. (B–C) Stimulation of proliferation of 
H1299 (B) or T24 (C) cells by medium conditioned by XRCC1 KD fibroblasts. TIG-1 fibroblasts were treated with the indicated siRNAs 
for 72 h, conditioned medium was then collected and used to feed cancer cells for five days.  (D) Stimulation of migration of H1299 
cells by medium conditioned by XRCC1 KD TIG-1 fibroblasts. Conditioned medium was generated as in (B), H1299 were then fed with 
the conditioned medium for 24 h before assessing their migration  using a wound healing assay. Faster wound closure indicates higher 
migration capacity. (E) Increased invasion of H1299 cells in co-culture with XRCC1 KD fibroblasts. TIG-1 fibroblasts were treated with 
the indicated siRNAs for 48 h and then cultured together with H1299 cells in Boyden chambers in the presence of conditioned medium. 
Images were acquired 24h after cell seeding and invading cells were counted. Scale bars: 200 µm. (F) Stimulation of invasion of H1299 
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Analysis of clinical stroma samples support 
the link between BER dysfunction and CAF 
phenotype
The phenotypical changes induced in normal 
fibroblasts by XRCC1 depletion support the idea that BER 
impairment could accelerate accumulation of DNA strand 
breaks in a pro-inflammatory tumour microenvironment. 
Thus, by acting as a trigger for trans-differentiation, BER 
impairment could possibly constitute an actual risk factor 
for the emergence of CAFs.
In order to understand whether this could be 
observed in vivo, we carried out a series of bioinformatics 
analyses on gene co-expression studies performed on 
human tissue samples. A negative correlation between 
CAF markers and XRCC1 expression was observed when 
analysing datasets that uniquely consist of stromal samples 
(Supplementary Figure 5A and Supplementary Table 3). 
Strikingly, restricting the analysis to fibroblast-only 
containing datasets yielded a marked negative correlation 
between XRCC1 expression and CAF markers (Figure 5A 
and Supplementary Table 3). A Gene Ontology enrichment 
analysis of this fibroblast-only dataset revealed that genes 
which positively correlated with XRCC1 expression 
were mainly involved in splicing/transcription, as well as 
DNA repair and cell-cycle related processes (Table 1 and 
Supplementary Table 4). Conversely, genes negatively 
correlated with XRCC1 expression were clustered into 
tissue remodelling and wound healing processes (Table 1 
and Supplementary Table 4). These findings are entirely 
consistent with the negative correlation between DNA 
repair and CAF markers shown in Figure 5A and indicate 
that a DNA repair deficiency in vivo could indeed be 
associated with appearance of a CAF-like phenotype. 
To investigate whether the same features could 
be observed in samples from tumour stroma gathered 
from clinical studies, two independent breast cancer 
datasets with a wide distribution of XRCC1 expression 
levels were analysed [20, 21] (Figure 5B). Comparison 
between tumour and control samples showed a substantial 
downregulation of XRCC1 in the tumour stroma (Figure 
5C). Interestingly, in XRCC1-low samples an increased 
expression of CAF markers and a concomitantly 
decreased expression of chromatin remodelling and 
DNA repair genes (e.g. UHRF1, TOP2A and BRE) 
was found (Figure 5D and Supplementary Figure 5B), 
validating the results obtained by our proteomics analysis. 
Importantly, when samples were separated into case 
and controls before the analysis, the expression pattern 
characterising XRCC1-low samples was preserved in 
tumour samples (Supplementary Figure 5C), suggesting 
that lower XRCC1 expression could potentially be used 
as prognostic indicator for tumours that are enriched in 
CAFs.
Altogether, these data show that XRCC1 
downregulation is associated with the emergence of 
CAF markers in human tumour stroma samples and fully 
confirm the observations we made in vitro.
Midostaurin sensitises BER deficient CAF-like 
cells to apoptosis
Finally, to investigate whether the information 
gathered by studying the XRCC1 KD model could be 
exploited to identify drugs targeting CAFs, we defined a 
“BER/CAF” signature encompassing the CAF markers 
consistently upregulated in response to BER-deficiency 
(Figures 5A and 6A). Using this signature and the 
OncomineTM database, we interrogated a drug sensitivity 
dataset [22] and identified midostaurin as a potential 
candidate targeting low-XRCC1 cells (Figure 6A). 
Midostaurin is a staurosporine derivative currently 
under investigation in several clinical trials (www.
clinicaltrials.gov). Staurosporines are potent multi-kinase 
inhibitors and can interfere with multiple functions 
essential to CAFs such as Ca2+ signalling [23] (Figure 3). 
Consistent with bioinformatics predictions, XRCC1 
KD fibroblasts showed hypersensitivity to midostaurin 
(Figure 6B and Supplementary Figure 6A). They were 
also sensitive to staurosporine (Supplementary Figure 6B) 
and to its analogue UCN-01 (Supplementary Figure 6D). 
Consistent with cell viability data, caspase activity 
assays confirmed that XRCC1 KD fibroblasts were 
greatly sensitised to apoptosis induced by midostaurin 
and other staurosporines; as expected, caspase activation 
was efficiently rescued by the broad caspase inhibitor 
ZVAD (Figure 6C, Supplementary Figure 6C and 6E). 
Lastly, midostaurin completely prevented the stimulatory 
ability of XRCC1 KD fibroblasts towards cancer cells, 
when delivered to XRCC1 KD/H1299 co-cultured 
spheroids (Figure 6D). Interestingly, H1299 cells were not 
particularly sensitive to midostaurin, suggesting that the 
drug indeed targeted CAFs (Supplementary Figure 6F).
This evidence indicates that XRCC1 KD CAF-like 
cells are hypersensitive to midostaurin, which is also 
effective in preventing their tumour promoting capability.
cells by XRCC1 KD fibroblasts. Cell spheroids were generated by culturing H1299 cells alone or by co-culturing H1299 cells together with 
TIG-1 fibroblasts (FBs) which were pretreated with the indicated siRNA. Two days after plating onto Matrigel, the spheroids were assessed 
for their tumorigenic potential by counting the number of invasive spikes (right). (G) Migration via network structure formation on three-
dimensional Matrigel. H1299-GFP cancer spheroids were plated on a Matrigel matrix. After spheroid seeding, a single cell suspension of 
either control (siCtrl) or XRCC1 KD fibroblasts (FBs) was added on top of the spheroid culture and imaged 24 h later. siXRCC1-treated 
fibroblasts created a network characterised by H1299-GFP cancer spheroid invasion (red arrows). Enlargements of these networks are 
shown on the right panel: XRCC1 KD fibroblasts (black arrows) appear to open the way for H1299-GFP cells (green arrows). Scale bars: 
100 µm. BF: Bright field. Representative fields are reported. Results are presented as mean ± SD of at least three independent experiments 
*p < 0.05; ***p < 0.001.
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DISCUSSION
Growth and invasion of cancer cells strongly 
depends on contributions from the surrounding stroma, 
which modifies and shapes the tumour microenvironment 
through the action of CAFs [14]. For this reason, finding 
drugs that specifically eliminate CAFs is a major focus 
for the development of anti-cancer therapies [24, 25]. 
We previously reported that proteomic changes in BER-
deficient fibroblasts are highly similar to those observed 
in CAFs and tumours [10]. Therefore, we hypothesised 
that the accumulation of unrepaired DNA strand breaks, 
a consequence of BER impairment, may constitute a 
mechanism underlying fibroblast reprogramming. 
Several explanations have been put forward to 
elucidate the origin of CAFs and how they maintain their 
phenotype, implicating genetic mutations, epigenetic 
modifications and persistent environmental effects [2, 15]. 
While the consequences of mutations and epigenetic 
modifications are still under investigation, the effect 
of persistent exposures to TGFβ or ROS have been 
well-documented to cause the trans-differentiation of 
resident fibroblasts into CAFs [5, 6]. In this study, we 
now demonstrate that the role of DNA damage in this 
phenomenon has been largely overlooked. 
Inflammation is a crucial feature in cancer [5, 26]. 
This complex phenomenon is characterised by the 
secretion of cytokines and a significant production of ROS 
[27]. We show here that fibroblasts persistently exposed 
to ROS or TGFβ do indeed accumulate unrepaired 
DNA lesions. Although the ability of ROS to generate 
DNA lesions is widely acknowledged [8], cytokines 
such as TGFβ are also capable of inducing oxidative 
stress and DNA damage [28–30]. This study confirms 
these observations in fibroblasts and takes the concept 
a step further, showing that long term exposure to ROS 
and TGFβ can trigger fibroblast trans-differentiation 
by exhausting the BER pathway and amplifying the 
generation of unrepaired DNA lesions. The XRCC1-
depletion model we used in this study strongly indicates 
that accumulation of SSBs are sufficient to induce trans-
differentiation because ROS and DSBs are undetectable in 
XRCC1 KD cells [12].
While providing a glimpse at the mechanisms 
driving CAF formation, this study also poses an important 
question about how DNA damage accumulation leads 
to genome-wide reprogramming. DNA damage has 
been observed to modulate a number of differentiation 
processes [31–33], although the mechanism(s) involved 
are unknown. Our proteomics analysis highlights major 
changes in proteins involved in chromatin remodelling and 
transcription. Thus, we speculate that generation of DNA 
repair defects and DNA damage on a whole-genome scale 
will likely lead to widespread chromatin reorganisation 
[34–37] and epigenetic modifications [38] and could 
be responsible for the transcriptional reprogramming 
observed in XRCC1 KD fibroblasts. Furthermore, we 
show that activation of stress-responsive transcription 
factors (e.g. ATF4) plays a crucial role in the trans-
differentiation process.
Our bioinformatics analyses indicate that the CAF-
like cells generated by depleting XRCC1 display a gene 
expression profile that is virtually indistinguishable from 
tumour stroma samples, whereby XRCC1 downregulation 
negatively correlates with expression of CAF markers. 
Intriguingly, downregulation of XRCC1 has been observed 
Table 1: Gene Ontology (G.O.) analysis of proteins that positively or negatively correlate with XRCC1 expression in 
fibroblasts 
Description FDR q value Enrichment
Cell cycle process 2.65E-87 5.75
Mitotic cell cycle process 1.12E-81 6.95
Mitotic cell cycle 2.29E-71 8.73
Cell cycle 8.88E-70 6.84
DNA metabolic process 1.94E-64 5.94
Extracellular matrix organization 5.79E-07 3.56
Extracellular structure organization 3.14E-07 3.55
Vesicle-mediated transport 9.29E-04 2.05
Collagen fibril organization 2.29E-03 8.60
Regulation of cell migration 2.09E-03 2.26
The top five G.O. terms that positively (lines 1–5) or negatively (lines 6–10) correlate with XRCC1 expression are shown. 
The full list of G.O. terms is provided in Supplementary Table 4.
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in a wide range of tumour types [39–42]. Low levels of 
XRCC1 expression have generally been associated with 
increased tumour aggressiveness and poorer outcome 
in triple negative breast cancer [41], reduced survival in 
gastric cancer [42] and unresponsiveness to radiotherapy 
in bladder cancer [43]. Moreover, low XRCC1 expression 
has recently been reported to impact prognosis in 
BRCA1-deficient breast cancers [44]. Our data suggest 
that XRCC1 expression levels in tumour stroma may 
be a crucial determinant for cancer progression and for 
the genesis of a tumour-promoting microenvironment. 
XRCC1 deficiency in the tumour stroma is likely, as 
demonstrated by our study, to act in synergy with ROS 
in the microenvironment and aggravate the accumulation 
of DNA breaks in order to amplify the pro-inflammatory 
response.
Targeting CAFs through either reversion of their 
phenotype, or selective elimination, is an appealing approach 
to cancer treatment. We demonstrate here that CAF-like cells 
generated by XRCC1 depletion are terminally committed to 
their “activated” status and therefore display an irreversible 
phenotype. Despite this, we devised a strategy that allows 
the selective elimination of a subset of CAFs showing BER 
deficiency. Our data indicate that midostaurin might be a 
promising drug to specifically neutralise BER-deficient 
stroma. Notably, midostaurin has recently been assigned a 
breakthrough therapy designation from the U.S. FDA for 
FLT3-mutated acute myeloid leukaemia (AML). The drug 
had previously been shown to induce apoptosis in keloid-
derived fibroblasts [45]. Additionally, midostaurin has 
been shown to efficiently override the stroma-associated 
cytoprotection of AML cells, when combined with an AKT 
inhibitor [46]. During physiological wound healing, activated 
Figure 5: Expression of BER genes in clinical stroma samples negatively correlates with CAF markers. (A) Plot showing 
the correlation between XRCC1 expression levels and the expression level of a number of human genes in 207 fibroblast datasets. BER 
and replication-associated genes (green dots) positively correlate with XRCC1 expression, whereas CAF markers (yellow and red dots) 
negatively correlate with XRCC1. Correlation is expressed as Z-score. A complete list of genes correlating with XRCC1 expression can be 
found in Supplementary Table 3. (B) Density plot depicting the distribution of tumour against control cases and the variation in XRCC1 
expression within the samples analysed. The dashed line shows the arbitrary threshold selected to separate samples on the basis of XRCC1 
expression level. Expression values correspond to the log2 median-centred values by sample. (C) Boxplot showing the median-centred 
expression of XRCC1 in tumour cases against controls using the threshold selected in (B). (D) Histogram showing the average expression 
of the indicated genes in low-XRCC1 vs. high-XRCC1 expressing samples.
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Figure 6: Midostaurin eliminates XRCC1 KD fibroblasts and negatively affects their stimulatory ability towards 
cancer cells. (A) Heat-map showing the expression of the genes selected from a “BER/CAF” signature in both midostaurin-resistant and 
-sensitive cell lines. Each column represents an individual cell line. The mean differential gene expression between midostaurin-resistant 
and -sensitive cell lines is reported for each individual gene of interest as a fold change (left-hand side). (B) Sensitivity of XRCC1 KD 
fibroblasts to midostaurin. TIG-1 fibroblasts were treated with the indicated siRNA for 48 h before exposure to increasing concentrations 
of midostaurin for 72 h. Cell viability was assessed using resazurin. (C) Increased apoptosis in XRCC1 KD fibroblasts after exposure 
to midostaurin. TIG-1 fibroblasts were treated as in (B). Caspase activity was assessed upon incubation with midostaurin (8 μM, 48 h). 
Specificity of the assay was confirmed by co-incubation of the drugs with the pan-caspase inhibitor zVAD. (D) Migration via network 
structure formation on three-dimensional Matrigel. H1299-GFP cancer spheroids were seeded on Matrigel. Either control (siCtrl) or XRCC1 
KD fibroblasts (FBs) were then added on top of the spheroid culture and imaged 24 h later. Midostaurin (1 μM) was used to pre-treat the 
fibroblasts and then administered to the spheroids for a further 24 h. Scale bars: 100 µm. BF: Bright field. Representative fields are reported.
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fibroblasts are eliminated by apoptosis [47]. Since CAFs are 
considered as their pathological equivalent, it is reasonable 
to assume that they could be eliminated in a similar fashion. 
This would suggest that BER-deficient CAF-like fibroblasts 
are in a pre-apoptotic state and should be sensitive to 
powerful apoptotic inducers such as staurosporine and 
midostaurin. It appears, therefore, that our data align with a 
growing body of evidence suggesting that midostaurin could 
have beneficial potential in multiple cancer types by virtue of 
its ability to target tumour stroma to apoptosis.
In summary, in this study we unveil a previously 
unrecognised concept, demonstrating that modulation of 
DNA repair in combination with inflammation stress could 
be a focal event during the formation of CAFs. These 
findings allowed us to identify midostaurin as a new drug 
targeting the tumour microenvironment. In combination 
with patient stratification based on BER status and 
capacity, our findings could constitute an extremely 
valuable approach to cancer treatment.
MATERIALS AND METHODS
Cell culture and drug treatments
Normal human fibroblasts TIG-1, AG16409 and 
WI38 were from the Coriell Institute Cell Repository. The 
non-small cell lung carcinoma cell line H1299 and A549 
were obtained from the American Type Culture Collection 
(ATCC), while the bladder carcinoma cell line T24 was 
kindly provided by Dr Anne Kiltie (University of Oxford). 
All cell lines were cultured in DMEM (Life Technologies) 
supplemented with either 15% (for the fibroblast cell 
lines) or 10% FBS (for cancer cell lines) at 37° C in a 
humidified atmosphere with 5% CO2. Cells were routinely 
checked for mycoplasma. Recombinant human TGF-β1 
(Peprotech) was used at the indicated concentration. The 
PLC inhibitor (edelfosine-Tocris), H2O2 (Sigma), the 
PDGF inhibitor (AG 1296-Millipore), staurosporine (Cell 
Guidance Systems), midostaurin (Sigma) and UCN-01 
(Millipore) were used at the indicated concentrations. 
siRNA transfections
siRNA transfections were carried out using the 
Lipofectamine RNAiMAX reagent (Life Technologies) 
according to the manufacturer’s protocol. Unless 
otherwise indicated, cells were transfected with 30 nM 
siRNA and analysed 72 hours after transfection. siRNA 
oligonucleotides were obtained from Eurogentec; a detailed 
list of the sequences can be found in the SI Material and 
Methods. Control transfections were carried out using a 
non-targeting siRNA (Eurogentec, SR-CL000-005).
Real-time PCR (qPCR)
Total RNA was extracted using the RNeasy kit 
(Qiagen) and cDNA was prepared using the SuperScript 
RT-PCR system (Life Technologies) as per manufacturer’s 
indications. Quantitative RT-PCR was performed using 
the Fast SYBR® Green Master Mix (Applied Biosystems) 
according to the manufacturer’s protocol. Reactions were 
carried out using a 7500 Fast Real-Time PCR System 
(Applied Biosystems). The comparative CT method was 
applied for quantification of gene expression; GAPDH 
and B2M were used as endogenous controls. A list of the 
primers can be found in the SI Material and Methods.
Comet assays
Cells were harvested by trypsinisation and analysed 
by alkaline comet assay as described elsewhere [12].
In vitro ligation assays
Nuclear cell extracts were prepared as described 
previously [10]. Ligation assays were carried out using 
1 mg of nuclear extract essentially as described in 
[48], with minor modifications. Briefly, reactions were 
performed in 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 
10 mM DTT, 1 mM ATP at 37° C for the indicated time; 
the oligonucleotide substrate (50 nM) as previously 
described [48] was 5′-labelled with IRDye®800 (IDT). 
Reactions were halted with 96% formamide and 10 
mM EDTA and analyzed by electrophoresis on a 20% 
denaturing polyacrylamide gel. The percentage of 
substrate converted to product was determined by using 
an Odyssey image analysis system (Li-Cor Biosciences).
Western blot
Whole cell extracts for Western blot were prepared 
as described previously [49]. A list of the antibodies used 
can be found in the SI Material and Methods. Detection 
and quantification was carried out using an Odyssey image 
analysis system (Li-Cor Biosciences).
3D spheroids co-culture invasion assays
Cancer multicellular spheroids were generated by 
using the hanging drop method [50]. Briefly, cells were 
detached with 2 mmol/L EDTA, counted, re-suspended 
in DMEM supplemented with methylcellulose (20%; 
Sigma) and GFR Matrigel matrix (1%, Corning) and 
incubated as droplets (25 μL) containing 103 cells for 48 
hours to generate multicellular aggregates. To generate 
“hybrid” cell spheroids, equal numbers of H1299-GFP 
cells and fibroblasts (transfected with either control or 
XRCC1 siRNA) were mixed (103 cells per droplet). For 
“hybrid” spheroids invasion, either cancer spheroids 
alone or “hybrid” aggregates were plated on Matrigel and 
cultured for two days in presence of medium conditioned 
by fibroblasts. Tumour cell invasion were apparent 
as projections from the spheroids after two days of co-
culture. The invasion was scored by counting the invasive 
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protrusions around the spheroids. At least 40 aggregates 
were counted per condition.
For network formation assay, cancer cell spheroids 
were washed and plated on Matrigel. 4 × 104 fibroblasts 
(transfected with either control or XRCC1 siRNA) 
were added to the spheroids as a single-cell suspension. 
Network formation and cancer cell migration were evident 
after 24 hours. Images were captured by using a Nikon 
10X/0.30 Ph1 objective.
Immunostaining
Immunostaining was carried out following standard 
procedures. Briefly, cells were fixed with paraformaldehyde 
(4% in PBS for 15 minutes), or methanol:acetone (1:1) 
for α-SMA staining. Permeabilisation was carried out 
using Triton X-100 (0.2% in PBS for 10 minutes at 4° C) 
and cells were saturated with 5% bovine serum albumin 
(BSA) in PBS for 1 hour. Incubation with antibodies (see 
Supplementary Material) was carried out in 5% BSA-PBS 
supplemented with 0.01% Tween 20. Alexa Fluor 488- 
and Alexa Fluor 594-conjugated secondary antibodies 
(Life Technologies) were used for indirect detection of 
the antigens. Hoechst 33342 (Life Technologies) was used 
to visualise nuclei. For determination of 53BP1 foci and 
cell elongation, images were acquired using an IN Cell 
Analyzer 1000 Imaging System and data were analysed 
using the IN Cell Investigator Software (GE Healthcare 
Life Sciences). Cell elongation is represented as a ratio 
of the shorter axis of the cell divided by the longer axis. 
Data are expressed as distribution of the mean from six 
experimental replicates.
Live cell imaging, wound healing assays and 
single-cell tracking
Cells were grown to 90% confluency before 
generation of a wound using a 200 µl tip. Cells were 
washed in PBS before adding fresh medium. Drug 
treatments were started 24 hours before wound scratching. 
Single-cell tracking commenced 5 hours after wound 
generation. The cells were observed under live microscopy 
using a Nikon Eclipse TE2000-E system for 20 hours 
capturing images every 30 minutes. Data were analysed 
using the ImageJ software and the MTrackJ plugin was 
used for single-cell tracking [51].
Cancer cell growth assays
Cancer cell growth stimulation was assessed by 
incubating cells with medium conditioned by XRCC1 
KD fibroblasts and by measuring their proliferation rate. 
In brief, TIG-1 cells were transfected with either a control 
or an XRCC1-targeting siRNA in serum-free medium. 
Conditioned medium was collected 72 hours after 
transfection and clarified by centrifugation at 1000 g for 5 
minutes. T24 or H1299 cells were pre-seeded 48 hours before 
incubation with conditioned medium; incubation was then 
carried out for several days, measuring proliferation every 
24 hours. Proliferation rate was measured by cell counting 
using Hoechst 33342 for T24 cells or using endogenous GFP 
fluorescence for H1299 cells. Fluorescence was quantified 
using a POLARstar Omega plate reader (BMG Labtech).
Collagen gel contraction assays
Collagen gel contraction assays were performed 
essentially as described in [52]. Briefly, 72 hours after 
siRNA treatment, cells were trypsinised, counted and 
mixed with Cultrexâ Rat Collagen I (Trevigen). The mix 
was neutralised by addition of 1 M NaOH and transferred 
to 24 well plates. The collagen gels were allowed to 
solidify for 30 minutes at 37° C and 600 µl of culture 
medium was added to each well. Gel plugs were gently 
detached from the wells and plates were incubated for 
24 hours at 37° C. To measure gel contraction, plugs were 
imaged using a ChemiDocTM system (BioRad) and gel 
areas were quantified using ImageJ software. Contractility 
was calculated by measuring the difference in area 
between the collagen plug and the entire well.
Boyden chamber invasion assays
Cancer cells (105) were cultured in triplicate in the 
top wells of Transwell Matrigel chambers (Corning) and 
allowed to invade towards fibroblasts (transfected with 
either control or XRCC1 siRNA) cultured in the bottom 
wells in conditioned medium supplemented with 10% 
FBS. Eighteen hours later invading cells were stained 
with Richard-Allan Scientific™ Three-Step Stain (Thermo 
Fisher Scientific), imaged and counted manually using 
Adobe Photoshop software.
Viability and apoptosis assays
Cell viability was assessed using resazurin (Sigma). 
Apoptosis induction was measured by using the Apo-
ONE® Homogeneous Caspase-3/7 Assay (Promega), 
according to the manufacturer’s protocol. Specificity of 
the signal was confirmed by co-incubating cells with the 
relevant drug and the pan-caspase inhibitor Z-VAD(OMe)-
FMK (Insight Biotechnology) during apoptosis induction.
Statistical analyses
Statistical analyses were performed by using the 
two-tailed Student’s t-test using either Microsoft Excel or 
SPSS (IBM). Sample size is indicated for each experiment.
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